Teva- Pharmaceutical Industries Ltd

NYSE: TEVA
$16.94
-$0.17 (-1.0%)
Closing Price on November 13, 2024

TEVA Articles

Rite Aid, Valeant, Calpine, and Teva all posted new 52-week lows on Thursday.
Valeant, Arena, Teva, and Frontier Communications all posted new 52-week lows on Tuesday.
Cenovus Energy, DryShips, Teva Pharmaceuticals, and OncoMed Pharmaceuticals all posted new 52-week lows Wednesday.
The March 31 short interest data have been compared with the previous figures, and short interest decreased in most of these selected pharmaceutical stocks.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Tuesday’s top analyst upgrades, downgrades and initiations include Apple, CVS Health, Priceline, Teva Pharmaceutical and Workday.
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
After Teva Pharmaceutical International reported fourth-quarter and full-year 2016 on Monday, only a few analysts weighed in initially, but the consensus is slowly growing more negative.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Intuitive Surgical, Restaurant Brands, Scorpio Tankers, Teva Pharmaceutical, Under Armour and Zillow.
Teva beat estimates on earnings and revenues for both the quarter and the fiscal year and its outlook for 2017 is better than the consensus estimates.
24/7 Wall St. has put together a preview of Cisco, Pepsico and some of the other most anticipated quarterly earnings reports expected this coming week.
Stocks were indicated marginally higher on Friday morning on what seems to be a very light news day. The Dow is still above 20,000 and the S&P 500 has gone above the 2,300 level. Even though the...
It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far the reaction has been quite positive.
Gilead Sciences, Gale Biopharma, Teva, and Fitbit post new 52-week lows Wednesday.